ArticleBlood2019
Analysis of 153 115 patients with hematological malignancies refines the spectrum of familial risk.
Article in Blood, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 72 citations in OpenAlex.
- Family history of haematological malignancy and prognosis across non-Hodgkin lymphoma subtypes.British journal of haematology · 2026Article
- Article
- Clustering of lymphoid neoplasms by cell of origin, somatic mutation and drug usage profiles: a multi-trait genome-wide association study.Blood cancer journal · 2025Article
- Rare germline ATM variants predispose to secondary cancer in chronic lymphocytic leukaemia patients.Cancer communications (London, England) · 2025Article
- Polyfunctional CD8Molecular oncology · 2025Article
- Risk of lymphoid malignancy associated with cancer predisposition genes.Blood cancer journal · 2025Article
- Investigating the influence of germlineHaematologica · 2025Article
- Evolution of myeloproliferative neoplasms from normal blood stem cells.Haematologica · 2025Review
- FaMMily Affairs: Dissecting inherited contributions to multiple myeloma risk.Seminars in hematology · 2025Review
- Novel epigenetic biomarkers for hematopoietic cancer found in twins.Acta oncologica (Stockholm, Sweden) · 2024Article
- The molecular map of CLL and Richter's syndrome.Seminars in hematology · 2024Review
- Clinical Risks for Chronic Lymphocytic Leukemia.Journal of the National Comprehensive Cancer Network : JNCCN · 2024Review
- Therapeutic Vaccines for Follicular Lymphoma: A Systematic Review.Pharmaceuticals (Basel, Switzerland) · 2024Review
- The inherited genetic contribution and polygenic risk score for risk of CLL and MBL: a narrative review.Leukemia & lymphoma · 2023Review
- Rare GermlineJournal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Article
- Contribution of rare and common coding variants to haematological malignancies in the UK biobank.Leukemia research reports · 2023Article
- Genetic lesions and targeted therapy in Hodgkin lymphoma.Therapeutic advances in hematology · 2023Review
- Role of Germline Predisposition to Therapy-Related Myeloid Neoplasms.Current hematologic malignancy reports · 2022Review
- Distinct germline genetic susceptibility profiles identified for common non-Hodgkin lymphoma subtypes.Leukemia · 2022Article
- Association between germline pathogenic variants in cancer-predisposing genes and lymphoma risk.Cancer science · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Estimating familial cancer risks is clinically important in being able to discriminate between individuals in the population at differing risk for malignancy. To gain insight into the familial risk for the different hematological malignancies and their possible inter-relationship, we analyzed data on more than 16 million individuals from the Swedish Family-Cancer Database. After identifying 153 115 patients diagnosed with a primary hematological malignancy, we quantified familial relative risks (FRRs) by calculating standardized incident ratios (SIRs) in 391 131 of their first-degree relatives. The majority of hematological malignancies showed increased FRRs for the same tumor type, with the highest FRRs being observed for mixed cellularity Hodgkin lymphoma (SIR, 16.7), lymphoplasmacytic lymphoma (SIR, 15.8), and mantle cell lymphoma (SIR, 13.3). There was evidence for pleiotropic relationships; notably, chronic lymphocytic leukemia was associated with an elevated familial risk for other B-cell tumors and myeloproliferative neoplasms. Collectively, these data provide evidence for shared etiological factors for many hematological malignancies and provide information for identifying individuals at increased risk, as well as informing future gene discovery initiatives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.